We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues.
Arrowhead Pharmaceuticals, ARWRSummary: Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.
- Recent ARWR Stock Price: $47.02
- Yearly Gain for ARWR stock: -25.10%
- Market Cap for ARWR stock: $4.97B
- P/E Ratio for ARWR stock: -31.072
Will ARWR's stock price go up? Is there an accurate ARWR stock forecast available?
TipRanks.com reports that Arrowhead Pharmaceuticals currently has n/a analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is n/a. The target pricing ranges from a high ARWR forecast of n/a down to a low forecast of n/a. Arrowhead Pharmaceuticals (ARWR)’s last closing stock price was $47.02 which would put the average price target at 52.06% upside.
In addition, TradingView issued a Buy rating for ARWR stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ARWR stock.
Other analysts covering ARWR include:
- Madhu Kumar of Goldman Sachs issued a Buy rating with the price target of $ 65 on 1 day ago
- Mayank Mamtani of B.Riley Financial issued a Buy rating with the price target of $ 65 on 1 day ago
- Keay Nakae of Chardan Capital issued a Buy rating with the price target of $ 82 on 4 days ago
- Mani Foroohar of SVB Securities issued a Hold rating with the price target of $ 35 on 3 weeks ago
If you are wondering if ARWR is a good stock to buy, here are 3rd party ratings for ARWR stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: n/a, n/a
What is the sentiment on the street regarding Arrowhead Pharmaceuticals? (Current ratings compiled by TipRanks.com)
- News Sentiment for ARWR stock: Very Bullish
- Blogger Consensus for ARWR stock: Neutral
- Media Buzz for ARWR stock: Low
- Insider Signal for ARWR stock: Positive
- Investor Sentiment for ARWR stock: Negative
- Hedge Fund signal for ARWR stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on ARWR stock including scouring the social networks like ARWR StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ARWR stock chart >>
Summary: Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells.
- Recent IOVA Stock Price: $12.31
- Yearly Gain for IOVA stock: -49.22%
- Market Cap for IOVA stock: $1.93B
- P/E Ratio for IOVA stock: -5.071
Will IOVA's stock price go up? Is there an accurate IOVA stock forecast available?
TipRanks.com reports that Iovance Biotherapeutics currently has 10 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $24.40. The target pricing ranges from a high IOVA forecast of $43.00 down to a low forecast of $13.00. Iovance Biotherapeutics (IOVA)’s last closing stock price was $12.31 which would put the average price target at 98.21% upside.
In addition, TradingView issued a Neutral rating for IOVA stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on IOVA stock.
Other analysts covering IOVA include:
- Geulah Livshits of Chardan Capital issued a Buy rating with the price target of $ 30 on 4 days ago
- Colleen M. Kusy of Robert W. Baird issued a Buy rating with the price target of $ 25 on 4 days ago
- Joseph Pantginis of H.C. Wainwright issued a Buy rating with the price target of $ 43 on 4 days ago
- Mara Goldstein of Mizuho Securities issued a Buy rating with the price target of $ 30 on 5 days ago
If you are wondering if IOVA is a good stock to buy, here are 3rd party ratings for IOVA stock:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 33% (84 out of 252)
What is the sentiment on the street regarding Iovance Biotherapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for IOVA stock: Neutral
- Blogger Consensus for IOVA stock: Bullish
- Media Buzz for IOVA stock: Very Low
- Insider Signal for IOVA stock: Positive
- Investor Sentiment for IOVA stock: Positive
- Hedge Fund signal for IOVA stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on IOVA stock including scouring the social networks like IOVA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for IOVA stock chart >>
Summary: Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
- Recent LLY Stock Price: $302.50
- Yearly Gain for LLY stock: 14.37%
- Market Cap for LLY stock: $287.42B
- P/E Ratio for LLY stock: 48.05
Will LLY's stock price go up? Is there an accurate LLY stock forecast available?
TipRanks.com reports that Eli Lilly & Co currently has 11 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $350.10. The target pricing ranges from a high LLY forecast of $395.00 down to a low forecast of $293.00. Eli Lilly & Co (LLY)’s last closing stock price was $302.50 which would put the average price target at 15.74% upside.
In addition, TradingView issued a n/a rating for LLY stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on LLY stock.
Other analysts covering LLY include:
- Terence Flynn of Morgan Stanley issued a Buy rating with the price target of $ 395 on 4 days ago
- Tim Anderson of Wolfe Research issued a Buy rating with the price target of $ 350 on 4 days ago
- Evan Seigerman of BMO Capital issued a Buy rating with the price target of $ 369 on 4 days ago
- David Risinger of SVB Securities issued a Buy rating with the price target of n/a on 1 week ago
If you are wondering if LLY is a good stock to buy, here are 3rd party ratings for LLY stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Bottom 44% (142 out of 252)
What is the sentiment on the street regarding Eli Lilly & Co? (Current ratings compiled by TipRanks.com)
- News Sentiment for LLY stock: Very Bearish
- Blogger Consensus for LLY stock: Bullish
- Media Buzz for LLY stock: Very High
- Insider Signal for LLY stock: Negative
- Investor Sentiment for LLY stock: Positive
- Hedge Fund signal for LLY stock: Negative
The stock market is extremely volatile, and you need to do your own research on LLY stock including scouring the social networks like LLY StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for LLY stock chart >>
Summary: Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.
- Recent ARVN Stock Price: $55.83
- Yearly Gain for ARVN stock: -40.22%
- Market Cap for ARVN stock: $2.97B
- P/E Ratio for ARVN stock: -12.443
Will ARVN's stock price go up? Is there an accurate ARVN stock forecast available?
TipRanks.com reports that Arvinas Holding Company currently has n/a analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is n/a. The target pricing ranges from a high ARVN forecast of n/a down to a low forecast of n/a. Arvinas Holding Company (ARVN)’s last closing stock price was $55.83 which would put the average price target at 52.55% upside.
In addition, TradingView issued a Buy rating for ARVN stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ARVN stock.
Other analysts covering ARVN include:
- Etzer Darout of BMO Capital issued a Buy rating with the price target of $ 95 on 4 days ago
- Mark Breidenbach of Oppenheimer issued a Buy rating with the price target of $ 102 on 4 days ago
- Andrew Berens of SVB Securities issued a Buy rating with the price target of $ 89 on 4 days ago
- Richard Law CFA of Credit Suisse issued a Buy rating with the price target of $ 78 on 4 days ago
If you are wondering if ARVN is a good stock to buy, here are 3rd party ratings for ARVN stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 33% (84 out of 252)
What is the sentiment on the street regarding Arvinas Holding Company? (Current ratings compiled by TipRanks.com)
- News Sentiment for ARVN stock: Very Bullish
- Blogger Consensus for ARVN stock: ―
- Media Buzz for ARVN stock: Medium
- Insider Signal for ARVN stock: ―
- Investor Sentiment for ARVN stock: Very Positive
- Hedge Fund signal for ARVN stock: Neutral
The stock market is extremely volatile, and you need to do your own research on ARVN stock including scouring the social networks like ARVN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ARVN stock chart >>
Summary: Alignment Healthcare Inc. is a consumer-centric platform delivering customized health care in the United States to seniors and those who need it most, the chronically ill and frail, through its Medicare Advantage plans. Alignment Healthcare Inc. is based in ORANGE, Calif.
- Recent ALHC Stock Price: $16.75
- Yearly Gain for ALHC stock: -17.12%
- Market Cap for ALHC stock: $3.14B
- P/E Ratio for ALHC stock: -20.481
Will ALHC's stock price go up? Is there an accurate ALHC stock forecast available?
TipRanks.com reports that Alignment Healthcare currently has n/a analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is n/a. The target pricing ranges from a high ALHC forecast of n/a down to a low forecast of n/a. Alignment Healthcare (ALHC)’s last closing stock price was $16.75 which would put the average price target at 21.13% upside.
In addition, TradingView issued a Buy rating for ALHC stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ALHC stock.
Other analysts covering ALHC include:
- Kevin Fischbeck of Bank of America Securities issued a Buy rating with the price target of $ 23 on 1 day ago
- Kevin Caliendo of UBS issued a Hold rating with the price target of $ 17 on 1 day ago
- Nathan Rich of Goldman Sachs issued a Buy rating with the price target of $ 21 on 1 day ago
- Sarah James of Barclays issued a Buy rating with the price target of $ 21 on 4 days ago
If you are wondering if ALHC is a good stock to buy, here are 3rd party ratings for ALHC stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 39% (99 out of 252)
What is the sentiment on the street regarding Alignment Healthcare? (Current ratings compiled by TipRanks.com)
- News Sentiment for ALHC stock: Very Bullish
- Blogger Consensus for ALHC stock: Bullish
- Media Buzz for ALHC stock: High
- Insider Signal for ALHC stock: Negative
- Investor Sentiment for ALHC stock: ―
- Hedge Fund signal for ALHC stock: Neutral
The stock market is extremely volatile, and you need to do your own research on ALHC stock including scouring the social networks like ALHC StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ALHC stock chart >>
Summary: Twist Bioscience Corporation operates as a biotechnology company. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development and DNA as a digital data storage medium. Twist Bioscience Corporation is headquartered in San Francisco, California.
- Recent TWST Stock Price: $56.56
- Yearly Gain for TWST stock: -49.88%
- Market Cap for TWST stock: $3.18B
- P/E Ratio for TWST stock: -14.288
Will TWST's stock price go up? Is there an accurate TWST stock forecast available?
TipRanks.com reports that Twist Bioscience currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $53.67. The target pricing ranges from a high TWST forecast of $56.00 down to a low forecast of $50.00. Twist Bioscience (TWST)’s last closing stock price was $56.56 which would put the average price target at -5.11% upside.
In addition, TradingView issued a n/a rating for TWST stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on TWST stock.
Other analysts covering TWST include:
- Puneet Souda of SVB Securities issued a Hold rating with the price target of $ 50 on 1 day ago
- Luke Sergott of Barclays issued a Buy rating with the price target of $ 55 on 4 days ago
- Steven Mah of Cowen & Co. issued a Buy rating with the price target of n/a on 2 months ago
- Rachel Vatnsdal of J.P. Morgan issued a Sell rating with the price target of $ 30 on 3 months ago
If you are wondering if TWST is a good stock to buy, here are 3rd party ratings for TWST stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 33% (84 out of 252)
What is the sentiment on the street regarding Twist Bioscience? (Current ratings compiled by TipRanks.com)
- News Sentiment for TWST stock: Neutral
- Blogger Consensus for TWST stock: Bullish
- Media Buzz for TWST stock: Very Low
- Insider Signal for TWST stock: Neutral
- Investor Sentiment for TWST stock: Very Positive
- Hedge Fund signal for TWST stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on TWST stock including scouring the social networks like TWST StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for TWST stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================